Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

May 30, 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

News Conference News EuroPCR 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Michael O'Riordan

May 29, 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

News Conference News EuroPCR 2025

Lower MACE Risk With FFR- vs Angio-Guided PCI in AS Patients: FAITAVI

May 22, 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

The ‘Smoker’s Paradox’ Takes a New Hit From Long-term Analysis

News Daily News

The ‘Smoker’s Paradox’ Takes a New Hit From Long-term Analysis

Yael L. Maxwell

March 24, 2025

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

News Daily News

SCAD Story Fleshed Out by Clues About Causes, Treatment Risks

Yael L. Maxwell

March 13, 2025

Early Invasive Treatment May Help Highest-Risk Women With NSTE ACS

News Daily News

Early Invasive Treatment May Help Highest-Risk Women With NSTE ACS

Yael L. Maxwell

March 10, 2025

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.